Clinical Trial

DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY

Study acronym: DAANCE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function while addressing patient-reported symptoms and participation in treatment. Toward this end, the investigators propose to study a noninvasive, social sensorimotor intervention - Adapted Argentine Tango - which targets motor control restoration, symptom alleviation, and treatment participation in concert.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-12-19; most recent amendment 2025-11-03.
Status change: Not Yet Recruiting → Recruiting 2025-03-13
Trial Details
NCT Number NCT06749210
Lead Sponsor Ohio State University Comprehensive Cancer Center
Collaborators: National Institute on Aging (NIA), Yale University, Emory University
Conditions Cancer of the Breast, Chemotherapy-induced Neuropathy
Enrollment 140 participants
Start Date 2025-02-19
Primary Completion 2029-08-15 (estimated)
Study Completion 2029-08-15 (estimated)
Updated on ClinicalTrials.gov 2025-11-05